2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.
Combinations that incorporate IDO inhibitors, STAT-3 inhibitors, and anti-KIR monoclonal antibodies, are doubling and even tripling response rates in patients with head and neck cancer, says Cohen.
Related Content: